488 related articles for article (PubMed ID: 28814763)
1. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
2. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.
Stein CK; Pawlyn C; Chavan S; Rasche L; Weinhold N; Corken A; Buros A; Sonneveld P; Jackson GH; Landgren O; Mughal T; He J; Barlogie B; Bergsagel PL; Davies FE; Walker BA; Morgan GJ
Oncotarget; 2017 Apr; 8(17):27854-27867. PubMed ID: 28427158
[TBL] [Abstract][Full Text] [Related]
3. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
Nat Commun; 2014; 5():2997. PubMed ID: 24429703
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O; Kaedbey R; Chow S; Danesh A; Dowar M; Li T; Li Z; Liu J; Mansour M; Masih-Khan E; Zhang T; Bratman SV; Oza AM; Kamel-Reid S; Trudel S; Pugh TJ
Nat Commun; 2017 May; 8():15086. PubMed ID: 28492226
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
[No Abstract] [Full Text] [Related]
7. Targeting the BRAF V600E mutation in multiple myeloma.
Andrulis M; Lehners N; Capper D; Penzel R; Heining C; Huellein J; Zenz T; von Deimling A; Schirmacher P; Ho AD; Goldschmidt H; Neben K; Raab MS
Cancer Discov; 2013 Aug; 3(8):862-9. PubMed ID: 23612012
[TBL] [Abstract][Full Text] [Related]
8. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
Rasche L; Kortüm KM; Raab MS; Weinhold N
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871078
[TBL] [Abstract][Full Text] [Related]
10. Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM; Vijaykumar T; Knoechel B; Lohr JG
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101146. PubMed ID: 32139012
[TBL] [Abstract][Full Text] [Related]
11. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
12. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
13. [Pathogenesis of multiple myeloma].
Rasche L; Weinhold N
Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
[TBL] [Abstract][Full Text] [Related]
14. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
[TBL] [Abstract][Full Text] [Related]
15. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.
Ndacayisaba LJ; Rappard KE; Shishido SN; Ruiz Velasco C; Matsumoto N; Navarez R; Tang G; Lin P; Setayesh SM; Naghdloo A; Hsu CJ; Maney C; Symer D; Bethel K; Kelly K; Merchant A; Orlowski R; Hicks J; Mason J; Manasanch EE; Kuhn P
Curr Oncol; 2022 Apr; 29(5):2954-2972. PubMed ID: 35621632
[TBL] [Abstract][Full Text] [Related]
16. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Bohn OL; Hsu K; Hyman DM; Pignataro DS; Giralt S; Teruya-Feldstein J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e65-8. PubMed ID: 24445188
[No Abstract] [Full Text] [Related]
19. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
